Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy.
Scheiner B, Kang B, Balcar L, Radu IP, Reiter FP, Adžić G, Guo J, Gao X, Yuan X, Cheng L, Gorgulho J, Schultheiss M, Peeters F, Hucke F, Ben Khaled N, Piseddu I, Philipp A, Sinner F, D'Alessio A, Pomej K, Saborowski A, Bathon M, Schwacha-Eipper B, Zarka V, Lampichler K, Nishida N, Lee PC, Krall A, Saeed A, Himmelsbach V, Tesini G, Huang YH, Vivaldi C, Masi G, Vogel A, Schulze K, Trauner M, Djanani A, Stauber R, Kudo M, Parikh ND, Dufour JF, Prejac J, Geier A, Bengsch B, von Felden J, Venerito M, Weinmann A, Peck-Radosavljevic M, Finkelmeier F, Dekervel J, Ji F, Wang HW, Rimassa L, Pinato DJ, Bouattour M, Chon HJ, Pinter M. Scheiner B, et al. Among authors: finkelmeier f. Hepatology. 2024 Nov 21. doi: 10.1097/HEP.0000000000001163. Online ahead of print. Hepatology. 2024. PMID: 39643944
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort.
de Castro T, Welland S, Jochheim L, Leyh C, Shmanko K, Finkelmeier F, Jeliazkova P, Jefremow A, Gonzalez-Carmona MA, Kandulski A, Roessler D, Ben Khaled N, Enssle S, Venerito M, Fründt TW, Schultheiß M, Djanani A, Pangerl M, Maieron A, Wirth TC, Marquardt JU, Greil R, Fricke C, Günther R, Schmiderer A, Bettinger D, Wege H, Scheiner B, Müller M, Strassburg CP, Siebler J, Ehmer U, Waidmann O, Weinmann A, Pinter M, Lange CM, Saborowski A, Vogel A. de Castro T, et al. Among authors: finkelmeier f. Hepatol Commun. 2024 Nov 4;8(11):e0562. doi: 10.1097/HC9.0000000000000562. eCollection 2024 Nov 1. Hepatol Commun. 2024. PMID: 39495153 Free PMC article.
Overcoming Communication Barriers in Clinical Care: A Digital Translation Platform.
Olsavszky V, Bazari M, Dai TB, Olsavszky A, Finkelmeier F, Friedrich-Rust M, Zeuzem S, Herrmann E, Leipe J, Michael FA, Westernhagen HV, Ballo O. Olsavszky V, et al. Among authors: finkelmeier f. JMIR Form Res. 2024 Oct 16. doi: 10.2196/63095. Online ahead of print. JMIR Form Res. 2024. PMID: 39451122 Free article.
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population.
Lo Prinzi F, Salani F, Rimini M, Rizzato MD, Antonuzzo L, Camera S, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Melo Alvim C, Roque R, Fornaro L, De Rosa A, Lavacchi D, Rossari F, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Viola MG, Silvestro L, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Ahcene Djaballah S, Zanuso V, Masi G, Lonardi S, Rimassa L, Casadei-Gardini A. Lo Prinzi F, et al. Among authors: finkelmeier f. Oncologist. 2024 Oct 19:oyae256. doi: 10.1093/oncolo/oyae256. Online ahead of print. Oncologist. 2024. PMID: 39427227 Free article.
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study.
Persano M, Casadei-Gardini A, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Mascia L, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Rimini M. Persano M, et al. Among authors: finkelmeier f. Oncology. 2024 Oct 11:1-13. doi: 10.1159/000541018. Online ahead of print. Oncology. 2024. PMID: 39396495
A New Drying Method of Thermolabile Flexible Endoscope Channels by Laminar and Turbulent Airflow: A Prospective, Randomized-Controlled, Single-Center, Proof-of-Concept Trial.
Michael FA, Jung M, Reimers M, Oschwald C, Mihm U, Welsch C, Walter D, Finkelmeier F, Masseli J, Pathil A, Dultz G, Puhlmann D, Diaz-Martinez L, Hack D, Lingwal N, Bojunga J, Kempf VAJ, Zeuzem S, Friedrich-Rust M. Michael FA, et al. Among authors: finkelmeier f. Am J Gastroenterol. 2024 Sep 23. doi: 10.14309/ajg.0000000000003093. Online ahead of print. Am J Gastroenterol. 2024. PMID: 39311431
Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort.
Mitzlaff K, Kirstein MM, Müller C, Venerito M, Olkus A, Dill MT, Weinmann A, Kocheise L, Busch A, Schulze K, Allo G, Waldschmidt DT, Barsch M, Bengsch B, Quante M, Gonzalez-Carmona MA, Himmelsbach V, Finkelmeier F, Kloeckner R, Schirmacher P, Marquardt JU, Zimpel C. Mitzlaff K, et al. Among authors: finkelmeier f. United European Gastroenterol J. 2024 Nov;12(9):1230-1242. doi: 10.1002/ueg2.12656. Epub 2024 Sep 20. United European Gastroenterol J. 2024. PMID: 39301763 Free PMC article.
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study.
Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Camera S, Stefanini B, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini M. Rossari F, et al. Among authors: finkelmeier f. Liver Cancer. 2024 Apr 10;13(5):522-536. doi: 10.1159/000537915. eCollection 2024 Oct. Liver Cancer. 2024. PMID: 39296620 Free PMC article.
A novel ultrasound-based algorithm for the detection of pancreatic stents placed for prophylaxis of post-ERCP pancreatitis: a prospective trial.
Michael FA, Feldmann C, Erasmus HP, Kubesch A, Goerguelue E, Knabe M, Abedin N, Heilani M, Hessz D, Graf C, Walter D, Finkelmeier F, Mihm U, Lingwal N, Zeuzem S, Bojunga J, Friedrich-Rust M, Dultz G. Michael FA, et al. Among authors: finkelmeier f. Ultraschall Med. 2024 Sep 25. doi: 10.1055/a-2407-9651. Online ahead of print. Ultraschall Med. 2024. PMID: 39222928 Free article. Clinical Trial. English.
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab.
Rimini M, Montes M, Amadeo E, Vitiello F, Kudo M, Tada T, Suda G, Shimose S, Lonardi S, Finkelmeier F, Salani F, Antonuzzo L, Marra F, Iavarone M, Cabibbo G, Foschi FG, Silletta M, Sacco R, Rapposelli IG, Scartozzi M, Nicoletta P, Aldrighetti L, Persano M, Camera S, Rossari F, Foti S, Kumada T, Hiraoka A, Iwamoto H, Rizzato MD, Himmelsbach V, Masi G, Corradi M, Celsa C, Fabio C, Frassineti GL, Cascinu S, Casadei-Gardini A, Presa J. Rimini M, et al. Among authors: finkelmeier f. Sci Rep. 2024 Aug 30;14(1):20200. doi: 10.1038/s41598-024-70928-z. Sci Rep. 2024. PMID: 39215078 Free PMC article.
112 results